SPRY.US ARS Pharmaceuticals, Inc

Healthcare Biotechnology USA Stocks
3.65 USD
Close of Nov 17, 2026
2.44 13.15
Market cap
USD 367M
P/E
-
P/B
20.82x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SPRY.US undervalued?

Graham number

The Graham number of ARS Pharmaceuticals, Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ARS Pharmaceuticals, Inc fundamental analysis

No fundamental analysis for ARS Pharmaceuticals, Inc yet.

ARS Pharmaceuticals, Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ARS Pharmaceuticals, Inc

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Full company profile